RSV Burden in Hong Kong: What RSV does to adults

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational study that will serially collect specimens from adults with community-acquired respiratory tract infections to understand the burden of RSV in the adult population. It aims to fill knowledge gaps about RSV impact, including hospitalizations and complications, in contrast to the well-described pediatric data. The study is led by the Chinese University of Hong Kong and conducted at a single site. No antiviral or vaccine intervention is being tested; rather, the study characterizes disease burden using observational methods. Eligible participants are adults 18 years and older with respiratory symptoms, and those unable to provide high-quality sputum or saliva are excluded.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Community-acquired respiratory tract infection symptoms
* Age \>= 18

Exclusion Criteria:

* Unable to provide a good quality of sputum and saliva

Where it's running

• Chinese University of Hong Kong
  Hong Kong, Hong Kong Recruiting

Study contacts

• Study coordinator: Ka Pang Chan, MBChB
• Email: chankapang@cuhk.edu.hk
• Phone: +852 35052211

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Zelicapavir versus placebo in adults at high risk for severe RSV

  This study tests whether zelicapavir, taken by mouth, can help adults with RSV who are at high risk for severe disease compared to placebo.

  Recruiting at 4 sites Phase 2/3 Enanta Pharmaceuticals, Inc · Cape Coral, Florida and 3 other locations · NCT07908381

• Immune Responses to RSV in Older Adults After Nasal RSV Challenge

  This study tests how the immune system responds to RSV in healthy adults aged 65–75 by giving them a controlled nasal infection in a monitored setting.

  Recruiting Imperial College London · London, London · NCT07713628

• Zelicapavir for RSV infection in young children

  This study tests whether Zelicapavir can help treat RSV infection in children aged 28 days to 36 months who are showing symptoms.

  Recruiting at 8 sites Phase 2 Enanta Pharmaceuticals, Inc · Bangkok and 7 other locations · NCT07482657

• Preparedness through community respiratory virus testing and engagement

  This program will offer community members regular testing for respiratory viruses like COVID-19, flu, and RSV and invite some people to join longer-term monitoring and household transmission follow-up.

  Recruiting at 2 sites University of California, San Diego · La Jolla, California and 1 other locations · NCT07147517

• Tdap and RSV vaccines in pregnancy: same visit versus separate visits

  This project will see if giving the RSV and Tdap vaccines together at one prenatal visit or at separate visits is safe and protects pregnant people and their babies better.

  Recruiting at 3 sites Phase 4 Canadian Immunization Research Network · Vancouver, British Columbia and 3 other locations · NCT07097012

• Monitoring and detection of influenza, RSV, and COVID-19 in adults with and without HIV in Lusaka

  This project will test methods to detect influenza, RSV, and COVID-19 in adults with and without HIV who have recent respiratory symptoms in Lusaka.

  Recruiting at 2 sites Centre for Infectious Disease Research in Zambia · Lusaka, Lusaka Province and 1 other locations · NCT07030075

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.